Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold

Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler H-G, Stammler A, Pfeiffer WD, Tschesche H (2001)
JOURNAL OF MEDICINAL CHEMISTRY 44(20): 3231-3243.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ;
Abstract / Bemerkung
We describe a new generation of heterocyclic nonpeptide matrix metalloproteinase (MMP) inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. A screening effort was utilized to identify some chiral 6-methyl-1,3,4-thiadiazines that are weak inhibitors of the catalytic domain of human neutrophil collagenase (cdMMP-8). Further optimization of the lead compounds revealed general design principles that involve the placement of a phenyl or thienyl group at position 5 of the thiadiazine ring, to improve unprimed side affinity; the incorporation of an amino group at position 2 of the thiadiazine ring as the chelating agent for the catalytic zinc; the placement of a N-sulfonamide-substituted amino acid residue at the amino group, to improve primed side affinity; and the attachment of diverse functional groups at position 4 or 5 of the phenyl or thienyl group at the unprimed side, to improve selectivity. The new compounds were assayed against eight different matrix metalloproteinases, MMP-1, cdMMP-2, cdMMP-8, MMP-9, cdMMP-12, cdMMP-13, cdMMP-14, and the ectodomain of MMP-14, respectively. A unique combination of the above-described modifications produced the selective inhibitor (2R)-N-[5-(4-bromophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)a mino]propanamide with high affinity for MMP-9 (K-i = 40 nM). X-ray crystallographic data obtained for cdMMP-8 cocrystallized with N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide gave detailed design information on binding interactions for thiadiazine-based MMP inhibitors.
Erscheinungsjahr
Zeitschriftentitel
JOURNAL OF MEDICINAL CHEMISTRY
Band
44
Zeitschriftennummer
20
Seite
3231-3243
ISSN
eISSN
PUB-ID

Zitieren

Schröder J, Henke A, Wenzel H, et al. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. JOURNAL OF MEDICINAL CHEMISTRY. 2001;44(20):3231-3243.
Schröder, J., Henke, A., Wenzel, H., Brandstetter, H., Stammler, H. - G., Stammler, A., Pfeiffer, W. D., et al. (2001). Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. JOURNAL OF MEDICINAL CHEMISTRY, 44(20), 3231-3243. doi:10.1021/jm010887p
Schröder, J., Henke, A., Wenzel, H., Brandstetter, H., Stammler, H. - G., Stammler, A., Pfeiffer, W. D., and Tschesche, H. (2001). Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. JOURNAL OF MEDICINAL CHEMISTRY 44, 3231-3243.
Schröder, J., et al., 2001. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. JOURNAL OF MEDICINAL CHEMISTRY, 44(20), p 3231-3243.
J. Schröder, et al., “Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold”, JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2001, pp. 3231-3243.
Schröder, J., Henke, A., Wenzel, H., Brandstetter, H., Stammler, H.-G., Stammler, A., Pfeiffer, W.D., Tschesche, H.: Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. JOURNAL OF MEDICINAL CHEMISTRY. 44, 3231-3243 (2001).
Schröder, J., Henke, A, Wenzel, Herbert, Brandstetter, H, Stammler, Hans-Georg, Stammler, A, Pfeiffer, WD, and Tschesche, Harald. “Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold”. JOURNAL OF MEDICINAL CHEMISTRY 44.20 (2001): 3231-3243.

19 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Synthesis and Evaluation of Aminothiazole-Paeonol Derivatives as Potential Anticancer Agents.
Tsai CY, Kapoor M, Huang YP, Lin HH, Liang YC, Lin YL, Huang SC, Liao WN, Chen JK, Huang JS, Hsu MH., Molecules 21(2), 2016
PMID: 26821004
3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction.
Yefidoff-Freedman R, Chen T, Sahoo R, Chen L, Wagner G, Halperin JA, Aktas BH, Chorev M., Chembiochem 15(4), 2014
PMID: 24458973
Room temperature synthesis and antibacterial activity of new sulfonamides containing n,n-diethyl-substituted amido moieties.
Ajani OO, Familoni OB, Wu F, Echeme JO, Sujiang Z., Int J Med Chem 2012(), 2012
PMID: 25374686
Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE, Gilmore JL, Yang A, Chen XT, Xue CB, Roderick J, Liu RQ, Covington MB, Decicco CP, Duan JJ., Bioorg Med Chem Lett 17(5), 2007
PMID: 17188863
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.
Verma RP, Hansch C., Bioorg Med Chem 15(6), 2007
PMID: 17275314
The design of inhibitors for medicinally relevant metalloproteins.
Jacobsen FE, Lewis JA, Cohen SM., ChemMedChem 2(2), 2007
PMID: 17163561
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE, Gilmore JL, Tebben A, Xue CB, Liu RQ, Decicco CP, Duan JJ., Bioorg Med Chem Lett 17(10), 2007
PMID: 17368021
Structural basis for the highly selective inhibition of MMP-13.
Engel CK, Pirard B, Schimanski S, Kirsch R, Habermann J, Klingler O, Schlotte V, Weithmann KU, Wendt KU., Chem Biol 12(2), 2005
PMID: 15734645
Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V., Biochimie 87(3-4), 2005
PMID: 15781327
Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.
Farkas E, Katz Y, Bhusare S, Reich R, Röschenthaler GV, Königsmann M, Breuer E., J Biol Inorg Chem 9(3), 2004
PMID: 14762707
A fully integrated protein crystallization platform for small-molecule drug discovery.
Hosfield D, Palan J, Hilgers M, Scheibe D, McRee DE, Stevens RC., J Struct Biol 142(1), 2003
PMID: 12718932
Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.
Supuran CT, Casini A, Scozzafava A., Med Res Rev 23(5), 2003
PMID: 12789686
Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents.
Zheng QH, Fei X, Liu X, Wang JQ, Bin Sun H, Mock BH, Lee Stone K, Martinez TD, Miller KD, Sledge GW, Hutchins GD., Nucl Med Biol 29(7), 2002
PMID: 12381456
The genesis of high-throughput structure-based drug discovery using protein crystallography.
Kuhn P, Wilson K, Patch MG, Stevens RC., Curr Opin Chem Biol 6(5), 2002
PMID: 12413557

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 11563922
PubMed | Europe PMC

Suchen in

Google Scholar